192 related articles for article (PubMed ID: 22480142)
21. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
22. Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection.
Bocchetta S; Maillard P; Yamamoto M; Gondeau C; Douam F; Lebreton S; Lagaye S; Pol S; Helle F; Plengpanich W; Guérin M; Bourgine M; Michel ML; Lavillette D; Roingeard P; le Goff W; Budkowska A
PLoS One; 2014; 9(3):e92140. PubMed ID: 24646941
[TBL] [Abstract][Full Text] [Related]
23. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
Watashi K; Shimotohno K
Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
[TBL] [Abstract][Full Text] [Related]
24. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon.
Ikeda M; Kato N
J Pharmacol Sci; 2007 Oct; 105(2):145-50. PubMed ID: 17928739
[TBL] [Abstract][Full Text] [Related]
25. NS5A--from obscurity to new target for HCV therapy.
Schmitz U; Tan SL
Recent Pat Antiinfect Drug Discov; 2008 Jun; 3(2):77-92. PubMed ID: 18673121
[TBL] [Abstract][Full Text] [Related]
26. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
[TBL] [Abstract][Full Text] [Related]
27. Small molecule inhibitors of HCV replication from pomegranate.
Reddy BU; Mullick R; Kumar A; Sudha G; Srinivasan N; Das S
Sci Rep; 2014 Jun; 4():5411. PubMed ID: 24958333
[TBL] [Abstract][Full Text] [Related]
28. Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.
Hartlage AS; Walker CM; Kapoor A
J Virol; 2020 May; 94(10):. PubMed ID: 32102885
[TBL] [Abstract][Full Text] [Related]
29. Soraphen A: A broad-spectrum antiviral natural product with potent anti-hepatitis C virus activity.
Koutsoudakis G; Romero-Brey I; Berger C; Pérez-Vilaró G; Monteiro Perin P; Vondran FW; Kalesse M; Harmrolfs K; Müller R; Martinez JP; Pietschmann T; Bartenschlager R; Brönstrup M; Meyerhans A; Díez J
J Hepatol; 2015 Oct; 63(4):813-21. PubMed ID: 26070407
[TBL] [Abstract][Full Text] [Related]
30. Fungus-Derived Neoechinulin B as a Novel Antagonist of Liver X Receptor, Identified by Chemical Genetics Using a Hepatitis C Virus Cell Culture System.
Nakajima S; Watashi K; Ohashi H; Kamisuki S; Izaguirre-Carbonell J; Kwon AT; Suzuki H; Kataoka M; Tsukuda S; Okada M; Moi ML; Takeuchi T; Arita M; Suzuki R; Aizaki H; Kato T; Suzuki T; Hasegawa H; Takasaki T; Sugawara F; Wakita T
J Virol; 2016 Oct; 90(20):9058-74. PubMed ID: 27489280
[TBL] [Abstract][Full Text] [Related]
31. Experimental models for hepatitis C virus (HCV): new opportunities for combating hepatitis C.
Trujillo-Murillo Kdel C; Garza-Rodríguez Mdel L; Martínez-Rodríguez HG; Barrera-Saldaña HA; Bosques-Padilla F; Ramos-Jiménez J; Rivas-Estilla AM
Ann Hepatol; 2004; 3(2):54-62. PubMed ID: 15257247
[TBL] [Abstract][Full Text] [Related]
32. N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly.
Schweitzer CJ; Zhang F; Boyer A; Valdez K; Cam M; Liang TJ
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118118
[TBL] [Abstract][Full Text] [Related]
33. Metabolic alterations and hepatitis C: From bench to bedside.
Chang ML
World J Gastroenterol; 2016 Jan; 22(4):1461-76. PubMed ID: 26819514
[TBL] [Abstract][Full Text] [Related]
34. Targeting cellular squalene synthase, an enzyme essential for cholesterol biosynthesis, is a potential antiviral strategy against hepatitis C virus.
Saito K; Shirasago Y; Suzuki T; Aizaki H; Hanada K; Wakita T; Nishijima M; Fukasawa M
J Virol; 2015 Feb; 89(4):2220-32. PubMed ID: 25473062
[TBL] [Abstract][Full Text] [Related]
35. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
36. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
37. Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis C virus.
Syed GH; Siddiqui A
Hepatology; 2011 Dec; 54(6):1936-46. PubMed ID: 21858850
[TBL] [Abstract][Full Text] [Related]
38. Antiviral Research--16th International Congress: HBV and HCV. 27 April-1 May 2003, Savannah, GA, USA.
Smee D
IDrugs; 2003 Jun; 6(6):518-21. PubMed ID: 12861975
[No Abstract] [Full Text] [Related]
39. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
40. Visualizing the Essential Role of Complete Virion Assembly Machinery in Efficient Hepatitis C Virus Cell-to-Cell Transmission by a Viral Infection-Activated Split-Intein-Mediated Reporter System.
Zhao F; Zhao T; Deng L; Lv D; Zhang X; Pan X; Xu J; Long G
J Virol; 2017 Jan; 91(2):. PubMed ID: 27852847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
